Serial changes in the coagulation system following clotting factor concentrate infusion

Area of Science:

• Hematology
• Coagulation science
• Internal medicine

Background:

• Christmas disease (hemophilia B) is a rare genetic bleeding disorder.
• Clotting factor concentrates are used for treatment, but their systemic effects require monitoring.
• Coagulation parameters can be altered by factor replacement therapy.

Purpose of the Study:

• To monitor coagulation system parameters in Christmas disease patients after factor concentrate infusion.
• To assess the transient effects of clotting factor concentrates on specific coagulation factors.
• To evaluate the safety and clinical implications of these induced changes.

Main Methods:

• Monitoring of coagulation factors (e.g., factor VIII, antithrombin III, fibrinogen) in patients.
• Analysis of blood samples at various time points post-infusion.
• Clinical observation for any adverse events or sequelae.

Main Results:

• A significant reduction in clotting factor VIII was observed in all five studies.
• Serum antithrombin III levels also showed a significant decrease across all studies.
• Plasma fibrinogen levels decreased in four out of five subjects.
• All induced abnormalities were transient with no reported clinical sequelae.

Conclusions:

• Clotting factor concentrate infusions in Christmas disease patients induce temporary, significant reductions in factor VIII and antithrombin III.
• These short-lived changes do not appear to cause immediate clinical complications.
• Further investigation is warranted to understand the impact of these concentrates in patients with co-existing liver disease.